The position of neoadjuvant chemotherapy within the treatment of ovarian cancer

Minerva Ginecologica

Volumn 58, Issue 5, 2006, Pages 393-403

  Van Gorp, T ^a   Amant, F ^a   Neven, P ^a   Berteloot, P ^a   Leunen, K ^a   Vergote, I ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chemotherapy; Neoadjuvant therapy; Ovarian neoplasms

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DOSE RESPONSE; FEASIBILITY STUDY; HUMAN; LAPAROSCOPY; META ANALYSIS; OVARY CANCER; PROGNOSIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CHEMOTHERAPY, ADJUVANT; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS;

EID: 33750902218     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999;10:87-92.
2. Meigs JV. Tumors of the pelvic organs. New York, NY: Macmillan; 1934.
3. Hudson CN. A radical operation for fixed ovarian tumours. J Obstet Gynaecol Br Commonw 1968;75: 1155-60.
4. Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol 1971;37:1-9.
5. Griffiths CT, Fuller AF. Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin N Am 1978;58:131-42.
6. Berek JS, Trope C, Vergote I. Surgery during chemotherapy and at relapse of ovarian cancer. Ann Oncol 1999;10:3-7.
7. Skipper HE. Thoughts on cancer chemotherapy and combination modality therapy (1974). JAMA 1974;230:1033-5.
8. Goldie JH, Coldman AJ. Mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation-rate. Cancer Treat Rep 1979;63:1727-33.
9. Smith JP, Day TG. Review of ovarian-cancer at the University-Of-Texas- Systems-Cancer-Center, Md-Anderson-Hospital-And-Tumor-Institute. Am J Obstet Gynecol 1979;135:984-93.
10. Bertelsen K, Jakobsen A, Andersen JE, Ahrons S, Pedersen PH, Kiaer H et al. A randomized study of cyclophosphamide and cisplatinum with or without doxorubicin in advanced ovarian-carcinoma. Gynecol Oncol 1987;28:161-9.
11. Marsoni S. Randomized comparison of cisplatin with cyclophosphamide cisplatin and with cyclophosphamide doxorubicin cisplatin in advanced ovarian-cancer. Lancet 1987;2:353-9.
12. Voest EE, Vanhouwelingen JC, Neijt JP. A meta-analysis of prognostic factors in advanced ovarian-cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives. Eur J Cancer Clin Oncol 1989;25:711-20.
13. Hunter RW, Alexander NDE, Soutter WP. Meta-analysis of surgery in advanced ovarian-carcinoma - Is maximum cytoreductive surgery an independent determinant of prognosis. Am J Obstet Gynecol 1992;166: 504-11.
14. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20: 1248-59.
15. Heintz APM, Hacker NF, Berek JS, Rose TP, Munoz AK, Lagasse LD. Cytoreductive surgery in ovarian-carcinoma - feasibility and morbidity. Obstet Gynecol 1986;67:783-8.
16. Potter ME, Partridge EE, Hatch KD, Soong SJ, Austin JM, Shingleton HM. Primary surgical therapy of ovarian-cancer - how much and when. Gynecol Oncol 1991;40: 195-200.
17. Redman JR, Petroni GR, Saigo PE, Geller NL, Hakes TB. Prognostic factors in advanced ovarian-carcinoma. J Clin Oncol 1986;4:515-23.
18. Neijt JP, Tenbokkelhuinink WW, Vanderburg MEL, Vanoosterom AT, Willemse PHB, Heintz APM et al. Randomized trial comparing 2 combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian-carcinoma. J Clin Oncol 1987;5:1157-68.
19. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian-cancer. Obstet Gynecol 1983;61:413-20.
20. Heintz APM, Vanoosterom AT, Baptist J, Trimbos MC, Schaberg A, Vandervelde EA et al. The treatment of advanced ovarian-carcinoma. 1. Clinical variables associated with prognosis. Gynecol Oncol 1988;30: 347-58.
21. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage-III epithelial ovarian-cancer. A Gynecologic Oncology Group-Study. Gynecol Oncol 1992;47:159-66.
22. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998;71:431-6.
23. Eisenkop SM, Spirtos NM. What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol 2001;82:489-97.
24. Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymphnode involvement in ovarian-cancer. Gynecol Oncol 1991;40:103-6.
25. Friedlander ML, Hedley DW, Swanson C, Russell P. Prediction of long-term survival by flow cytometric analysis of cellular Dna content in patients with advanced ovarian-cancer. J Clin Oncol 1988;6:282-90.
26. Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 2004;190:910-22.
27. Kehoe S, Powell J, Wilson S, Woodman C. The influence of the operating surgeons specialization on patient survival in ovarian-carcinoma. Br J Cancer 1994;70: 1014-7.
28. Wright JD, Herzog TJ, Powell MA. Morbidity of cytoreductive surgery in the elderly. Am J Obstet Gynecol 2004;190:1398-400.
29. Farias-Eisner R, Teng F, Oliveira M, Leuchter R, Karlan B, Lagasse LD et al. The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol 1994;55:108-10.
30. Eisenkop SM, Nalick RH, Wang HJ, Teng NNH. Peritoneal implant elimination during cytoreductive surgery for ovarian-cancer - impact on survival. Gynecol Oncol 1993;51:224-9.
31. vanDam PA, Tjalma W, Weyler J, Vanoosterom AT, Buytaert P. Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: a prospective randomized trial. Am J Obstet Gynecol 1996;174: 943-50.
32. Naik R, Nordin A, Cross PA, Hemming D, Lopes AD, Monaghan JM. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases. Gynecol Oncol 2000;78:171-5.
33. Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H et al. Prognostic factors of stage FV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol 2001;81:398-403.
34. Zang RY, Zhang ZY, Cai SM, Li ZT, Chen J, Tang MQ et al. Cytoreductive surgery for stage IV epithelial ovarian cancer. J Exp Clin Cancer Res 1999;18:449-54.
35. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-34.
36. Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC et al. A phase III randomised study of interval secondary cytoreducion in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. Proceedings of ASCO 2002;21:201a.
37. Donadio M, Bonardi G, Iberti V, Bertetto O, Carnino F, Iskra L et al. The role of induction chemotherapy in inoperable ovarian cancer. Tumori 1989;75:609-14.
38. Lawton FG, Redman CWE, Luesley DM, Chan KK, Blackledge G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian-cancer. Obstet Gynecol 1989;73:61-5.
39. Tummarello D, Menichetti ET, Miseria S, Torresi U, Guidi F, Gramazio A et al. Advanced epithelial ovarian cancer: no difference in survival rate between exploratory laparotomy and inadequate debulking surgery as treatment approach before chemotherapy. J Chemother 1990;2:260-3.
40. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovariancancer. Gynecol Oncol 1991;42:146-50.
41. Lim JT, Green JA. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin Oncol (R Coll Radiol) 1993;5:198-202.
42. Shimizu Y, Hasumi K. [Treatment of stage III and FV ovarian cancer-is neoadjuvant chemotherapy effective?]. Nippon Sanka Fujinka Gakkai Zasshi 1993;45: 1007-14. Japanese.
43. Onnis A, Marchetti M, Padovan P, Castellan L. Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynaecol Oncol 1996;17:393-6.
44. Surwit E, Childers J, Atlas I, Nour M, Hatch K, Hallum A et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 1996;6:356-61.
45. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 1999;72:93-9.
46. Ansquer Y, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma - A French multicenter study. Cancer 2001;91:2329-34.
47. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 2001;92:2585-91.
48. Recchia F, De Filippis S, Rosselli M, Saggio G, Carta G, Rea S. Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study. Eur J Gynaecol Oncol 2001;22:287-91.
49. Kayikcioglu F, Kose MF, Boran N, Caliskan E, Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 2001;11:466-70.
50. Ushijima K, Ota S, Komai K, Matsuo G, Motoshima S, Honda S et al. Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. Int Surg 2002;87:185-90.
51. Fanfani F, Ferrandina G, Corrado G, Fagotti A, Zakut HV, Mancuso S et al. Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients. Oncology 2003;65:316-22.
52. Shibata K, Kikkawa F, Mika M, Suzuki Y, Kajiyama H, Ino K et al. Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: survival benefit and prognostic factors. Int J Gynecol Cancer 2003;13: 587-92.
53. Morice P, Dubernard G, Rey A, Atallah D, Pautier P, Pomel C et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg 2003;197: 955-63.
54. Morice P, Brehier-Ollive D, Rey A, Atallah D, Lhomme C, Pautier P et al. Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-nonexposed study. Ann Oncol 2003;14:74-7.
55. Mazzeo F, Berliere M, Kerger J, Squifflet J, Duck L, D'Hondt V et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 2003;90:163-9.
56. Vrscaj MU, Rakar S. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study. Eur J Gynaecol Oncol 2002;23:405-10.
57. Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 2003;88:9-16.
58. Le T, Faught W, Hopkins L, Fung Kee FM. Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer. Int J Gynecol Cancer 2005;15:770-5.
59. Hegazy MA, Hegazi RA, Elshafei MA, Setit AE, Elshamy MR, Eltatoongy M et al. Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World J Surg Oncol 2005;3:57.
60. Loizzi V, Cormio G, Resta L, Rossi CA, Di Gilio AR, Cuccovillo A et al. Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study. Int J Gynecol Cancer 2005;15:217-23.
61. Lee SJ, Kim BG, Lee JW, Park CS, Lee JH, Bae DS. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynaecol Res 2006;32: 99-106.
62. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006.
63. Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian-carcinoma. J Clin Oncol 1993;11:166-72.
64. Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 2000;89:1532-40.
65. Tate S, Hirai Y, Takeshima N, Hasumi K. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. Gynecol Oncol 2005;96:143-9.
66. Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR et al. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 2004;190:910-25.
67. Gryspeerdt S, Clabout L, Van Hoe L, Berteloot P, Vergote IB. Intraperitoneal contrast material combined with CT for detection of peritoneal metastases of ovarian cancer. Eur J Gynaecol Oncol 1998;19:434-7.
68. Vergote I, Marquette S, Amant F, Berteloot P, Neven P. Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma. Int J Gynecol Cancer 2005;15:776-9.